

## SenzaGen wins its largest order for non-animal testing with GARD® – value SEK 4.2m

Lund, June 21, 2022

**SenzaGen has secured an order for non-animal testing with GARD®skin Dose-Response from a larger international industry association. The order, valued at SEK 4.2 million, represents the largest single purchasing commitment of GARD® test to date, confirming the strength and the many unique application areas of the technology. The tests will be performed in SenzaGen's GLP-certified laboratory in Lund during the coming six to nine months.**

SenzaGen's unique GARD®skin Dose-Response test provides the customer with information on the dosage at which skin sensitizers can be used in consumer products without inducing skin allergies in humans.

"The transition from animal testing to methods that provide better results for humans is ongoing in the toxicology testing industry and SenzaGen has taken the lead in skin sensitization. The order, which is our largest to date, is a result of the GARD® technology's unique capabilities to provide quantitative information and the strong relationship we have built with the customer over a long time. It marks a major milestone for the company and significantly strengthens our market position. We are very much looking forward to providing the customer with valuable data to determine safe levels for substances in humans, a need that the industry has expressed for a long time", says Peter Nählstedt, President and CEO, SenzaGen AB.

GARD®skin Dose-Response is a unique non-animal test that provides quantitative information on the concentration at which a substance causes allergy. The test enables companies in industries including cosmetics, pharmaceuticals and chemicals to identify the concentration of a substance at which it is safe for human use, which serves as a crucial basis for prioritization and decision-making in research and development. The test is an expanded application domain of GARD®skin, and it is one of the first of its kind on the market.

### Contacts

---

**Peter Nählstedt**, President and CEO, SenzaGen AB

Email: [peter.nahlstedt@senzagen.com](mailto:peter.nahlstedt@senzagen.com) | Mobile: +46 700 23 44 31

**Tina Dackemark Lawesson**, VP Marketing & Communications

Email: [tina.lawesson@senzagen.com](mailto:tina.lawesson@senzagen.com) | Mobile: +46 708 20 29 44



## About us

---

SenzaGen aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® test platform, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: [www.senzagen.com](http://www.senzagen.com).

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, [info@fnca.se](mailto:info@fnca.se), is the company's Certified Adviser.

*This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-06-21 17:08 CEST.*

## Attachments

---

[SenzaGen wins its largest order for non-animal testing with GARD® – value SEK 4.2m](#)